{"log_id": 5337726093241974926, "direction": 0, "words_result_num": 33, "words_result": [{"probability": {"variance": 0.020383, "average": 0.923334, "min": 0.407271}, "location": {"width": 765, "top": 172, "height": 33, "left": 217}, "words": "拉米夫定治疗失效的忠者:22%的拉米夫定失效病人在口服想替卡书1.0mg/48周后,病"}, {"probability": {"variance": 0.014539, "average": 0.953247, "min": 0.455739}, "location": {"width": 767, "top": 210, "height": 34, "left": 214}, "words": "载量达到K300拷贝/ml.对血清 HBV DNA在可测出水平的病人进行基因型分析,结果表明"}, {"probability": {"variance": 0.000176, "average": 0.976487, "min": 0.963215}, "location": {"width": 49, "top": 148, "height": 106, "left": 1090}, "words": "理件"}, {"probability": {"variance": 0.019165, "average": 0.927759, "min": 0.438999}, "location": {"width": 756, "top": 251, "height": 32, "left": 214}, "words": "在原先就有拉米夫定耐药变异(rtL180和/或tM204V/1)的病人中,有7%(13/189)"}, {"probability": {"variance": 0, "average": 0.803773, "min": 0.803773}, "location": {"width": 25, "top": 250, "height": 18, "left": 1101}, "words": "一"}, {"probability": {"variance": 0.021894, "average": 0.900763, "min": 0.437528}, "location": {"width": 768, "top": 289, "height": 34, "left": 211}, "words": "的病人在48周内出现rtI169,rt184,rtS202和/或rtM250等位点与恩替卡韦耐药相关的"}, {"probability": {"variance": 0.005831, "average": 0.976388, "min": 0.594315}, "location": {"width": 769, "top": 328, "height": 32, "left": 208}, "words": "置换变异,在这13名发生变异的病人中,有3名病人在48周之内发生了病毒学反弹( HBV DNA"}, {"probability": {"variance": 0.011414, "average": 0.957522, "min": 0.549675}, "location": {"width": 570, "top": 368, "height": 33, "left": 207}, "words": "从最低点上升≥1个10g),多数病人在48周之后发生了病毒学反弹"}, {"probability": {"variance": 0.040148, "average": 0.883725, "min": 0.536675}, "location": {"width": 77, "top": 441, "height": 22, "left": 208}, "words": "交叉耐药"}, {"probability": {"variance": 0.005322, "average": 0.972828, "min": 0.671116}, "location": {"width": 712, "top": 469, "height": 36, "left": 263}, "words": "抗乙肝病毒的核苷类似物药物中已发现有交叉耐药现象,在细胞试验中发现恩替卡"}, {"probability": {"variance": 0.016521, "average": 0.936247, "min": 0.455318}, "location": {"width": 767, "top": 508, "height": 37, "left": 207}, "words": "节对拉米夫定耐药(rtL180M和/或rtM204V/I)的病毒株的抑制作用比野生株减弱8至30"}, {"probability": {"variance": 0.021663, "average": 0.920093, "min": 0.379301}, "location": {"width": 771, "top": 548, "height": 35, "left": 202}, "words": "倍思替卡韦对阿德福耐药性变异( HBV DNA多聚酶rtN236T或rtA181V变异)的重组病"}, {"probability": {"variance": 0.014351, "average": 0.95991, "min": 0.428292}, "location": {"width": 758, "top": 585, "height": 36, "left": 201}, "words": "也完全敏感。体外试验显示,从拉米夫定和恩替卡韦都失效的病人中分离出来的病株"}, {"probability": {"variance": 0.009749, "average": 0.96422, "min": 0.528516}, "location": {"width": 407, "top": 628, "height": 32, "left": 200}, "words": "对阿德福韦敏感,但对拉米夫定依然保持附药性"}, {"probability": {"variance": 0.037251, "average": 0.882697, "min": 0.54856}, "location": {"width": 81, "top": 698, "height": 23, "left": 197}, "words": "毒理研究"}, {"probability": {"variance": 0.024535, "average": 0.90297, "min": 0.631957}, "location": {"width": 79, "top": 737, "height": 23, "left": 197}, "words": "遗传霉性"}, {"probability": {"variance": 0.010114, "average": 0.959136, "min": 0.601061}, "location": {"width": 727, "top": 763, "height": 38, "left": 240}, "words": "在人类淋巴细胞培养的实验中,发现恩替卡韦是染色体断裂诱导剂。在Ames实验(使"}, {"probability": {"variance": 0.01527, "average": 0.942883, "min": 0.370871}, "location": {"width": 773, "top": 803, "height": 38, "left": 193}, "words": "用伤寒杆菌,大肠杆菌,使用或不用谢激活剂)、基因突变实验和叙利亚仓鼠胚胎细胞转"}, {"probability": {"variance": 0.010226, "average": 0.965892, "min": 0.49732}, "location": {"width": 764, "top": 841, "height": 39, "left": 192}, "words": "染实验中,发现恩替卡书不是突变诱导剂,在大鼠的经口给药微核实验和DNA修复实验中"}, {"probability": {"variance": 0.031284, "average": 0.92491, "min": 0.457586}, "location": {"width": 158, "top": 891, "height": 26, "left": 192}, "words": "恩替卡韦也呈阴性"}, {"probability": {"variance": 4e-06, "average": 0.99855, "min": 0.995024}, "location": {"width": 80, "top": 957, "height": 23, "left": 192}, "words": "生殖毒性"}, {"probability": {"variance": 0.006103, "average": 0.955218, "min": 0.628531}, "location": {"width": 731, "top": 980, "height": 42, "left": 233}, "words": "在生殖毒性研究中,连续4周给予恩替卡韦,剂量最高达30mg/kg,在给药剂量超过人"}, {"probability": {"variance": 0.002182, "average": 0.973761, "min": 0.751251}, "location": {"width": 776, "top": 1020, "height": 41, "left": 189}, "words": "体最高推荐剂量1mg/天的90倍时,没有发现雄性和雌性大鼠的生育力受到影响。在恩替卡"}, {"probability": {"variance": 0.006951, "average": 0.966811, "min": 0.622647}, "location": {"width": 775, "top": 1060, "height": 40, "left": 188}, "words": "韦的毒理学研究中,当剂量至人体剂量的35倍或以上时,发现啮齿类动物与狗出现了输精"}, {"probability": {"variance": 0.0008, "average": 0.987025, "min": 0.891855}, "location": {"width": 428, "top": 1104, "height": 33, "left": 186}, "words": "管的退行性变。在猴子实验中,未发现睾丸的改变"}, {"probability": {"variance": 0.013647, "average": 0.945962, "min": 0.522602}, "location": {"width": 729, "top": 1135, "height": 39, "left": 233}, "words": "在大鼠和家兔的生殖毒性研究中,口服本品的剂量达200和16mg/k/天,即相当于人"}, {"probability": {"variance": 0.007072, "average": 0.954207, "min": 0.624526}, "location": {"width": 780, "top": 1172, "height": 43, "left": 184}, "words": "体最高剂量1.0mg/天的28倍(对于大鼠)和212倍(对于家兔)时,没有发现胚胎和母体"}, {"probability": {"variance": 0.018476, "average": 0.948221, "min": 0.352321}, "location": {"width": 779, "top": 1213, "height": 41, "left": 184}, "words": "毒性在大鼠实验中,当母鼠的用药量相当于人体剂量3100倍时,观察到恩卡对胚胎"}, {"probability": {"variance": 0.009113, "average": 0.948881, "min": 0.659151}, "location": {"width": 758, "top": 1249, "height": 43, "left": 201}, "words": "胎鼠的毒性作用(重吸收)、体重降低、尾巴和脊锥形态异常和骨化水平降低脊锥、趾"}, {"probability": {"variance": 0.007089, "average": 0.964433, "min": 0.535411}, "location": {"width": 776, "top": 1287, "height": 44, "left": 183}, "words": "骨和指骨),并观察到额外的腰椎和肋骨,在家兔实验中,对雌兔的用药量为体的1.0mg/"}, {"probability": {"variance": 0.007478, "average": 0.947881, "min": 0.662597}, "location": {"width": 775, "top": 1326, "height": 42, "left": 185}, "words": "日剂量的883倍时,观察到对胚胎一胎兔的游性作用(吸收)、骨化水平降低(骨》,并且"}, {"probability": {"variance": 0.012865, "average": 0.960494, "min": 0.363564}, "location": {"width": 778, "top": 1363, "height": 42, "left": 182}, "words": "第13根肋骨的发生率增加。在对出生前和出生大鼠口服思替卡韦的研究中发现用药量火"}, {"probability": {"variance": 0.011985, "average": 0.947317, "min": 0.54207}, "location": {"width": 387, "top": 1408, "height": 37, "left": 181}, "words": "于人的1mg/日剂量的94倍未对后代产生影响"}], "language": 3}